Core Viewpoint - The approval of SYH2069 injection by the National Medical Products Administration of China marks a significant milestone for the company, as it is expected to be the first GLP-1/GIP receptor dual agonist to enter clinical trials in China, following its prior approval by the FDA for trials in the United States [1] Group 1: Product Development - SYH2069 injection is designed to selectively activate the cAMP pathway while significantly reducing β-arrestin recruitment, which minimizes receptor internalization and desensitization, thereby enhancing efficacy and duration of effect [1] - The product utilizes a long half-life modification platform technology, aiming for deeper and more sustained weight loss effects [1] Group 2: Clinical Research Findings - In studies involving diet-induced obesity (DIO) mice and non-human primates, SYH2069 demonstrated significantly superior weight loss and metabolic improvement compared to existing market products [1] - Toxicology studies in non-human primates indicated good tolerability of the product, with no observed vomiting or gastrointestinal adverse reactions [1] Group 3: Clinical Application and Value - The approved clinical indication for SYH2069 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1] - The product also shows potential for improving blood glucose control in adults with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1]
石药集团：GLP -1 / GIP受体双偏向性激动多肽注射液(SYH2069注射液)在中国获临床试验批准